Takeda Pharmaceutical reported a 1.7% revenue decline in FY2025 to $28.4 billion, mainly due to generic competition for its drug Vyvanse. The company is implementing a transformation program and cost-cutting measures targeting $1.3 billion in annual savings by FY2028. Takeda's future growth depends on the successful launch of three new drugs: oveporexton, rusfertide, and zasocitinib. Despite current challenges, Takeda's valuation is considered reasonable, supporting a "Buy" recommendation as the market may undervalue these upcoming assets.
Over the past six months, Costco's stock has fallen by 10%, contrasting with the S&P 500's 17% gain. This decline has sparked debate on whether Costco's shares, now trading under $900, represent a buying opportunity. Investors are weighing if the pri...
Elon Musk has confirmed that his company is in discussions with Terafab, marking a potential new chip manufacturing partner alongside Intel, which has been the only named chip partner until now. This development could diversify the supply chain and e...
Ripple's XRP token experienced bullish momentum in August, breaking key resistance and maintaining support around $1.45. Despite some short-term selling pressure and price corrections, technical indicators suggest a long-term uptrend. Traders are wat...
Arthur Hayes, co-founder of Bitmex, stated in an interview that Michael Saylor's Bitcoin investment strategy no longer drives the market due to the rise of U.S. spot Bitcoin ETFs, which offer investors easier access to Bitcoin. Hayes highlighted that...
GoldMining Inc. announced initial assay results from its 2026 diamond drilling program at the Yarumalito Project in Colombia, confirming nearly 400 meters of continuous gold-copper mineralization from surface in drill hole YAR-45. The results validat...
